Cmed Group Selected as Preferred Provider to a Consortium of Product Development Partnerships

Cmed’s Technology and Services to Help With Clinical Development in Developing Countries

HORSHAM, England--(BUSINESS WIRE)-- Cmed Group, an innovative clinical trials services and advanced software provider, announced today that it has been selected as one of six preferred providers offering its clinical research expertise to a consortium of 14 global health Product Development Partnerships (PDPs). The PDPs are working to develop and deliver affordable treatments and vaccines that will help improve the lives of the some of the world’s most vulnerable people, especially those in developing countries.

Cmed Group is expected to provide the PDPs with a wide range of eClinical technology capabilities, such as electronic data capture (EDC) and data management, and CRO services through its two divisions: Cmed Technology, an eClinical technology provider, and Cmed Clinical Services, a full-service CRO.

During the next two years, the PDPs are expected to fund more than 100 clinical trials. These Phase I through Phase IV trials will focus on infectious diseases, including HIV, malaria and tuberculosis (TB).

Cmed Technology has been employed by the Aeras, a non-profit PDP research organization developing new TB vaccines and ensuring that they are distributed to all who need them around the world. As part of a Phase II double-blind, randomized clinical trial of a TB vaccine candidate in infants, Aeras used Cmed Technology’s Timaeus on-demand eClinical platform to electronically capture data from three clinical sites in South Africa, while managing and analyzing the data from its U.S. headquarters in Rockville, Md.

“Cmed Group feels privileged to have been selected to help the PDPs with the development of new medicines in Third-World Countries,” said Dr. David Connelly, CEO of Cmed Group. “We hope to provide a full range of clinical services and our Timaeus on-demand eClinical platform to help perform electronic data capture more efficiently and accurately as well as rapidly communicate and manage data across mobile phone networks or satellites in extremely challenging areas with limited or no Internet connectivity. The end result will be highly rewarding—bringing the prospect of better health one step closer for the world’s poor.”

The PDPs are funded in part by the Bill & Melinda Gates Foundation.

About Cmed Group

Cmed Group was founded in 2000 by former senior pharmaceutical and clinical research executives with a vision of combining deep, full-spectrum experience in clinical services with innovative technology to provide customers a better way to manage clinical data. Cmed Group includes Cmed Clinical Services, a full-service contract research organization (CRO), and Cmed Technology, an eClinical technology provider. Its diverse, global customers include pharmaceutical and biotechnology companies, academic institutions, CROs, and not-for-profit research organizations. Its main office is in Horsham, West Sussex UK, with additional offices in Timisoara, Romania; Murray Hill, NJ USA and Durham (Research Triangle Park), NC USA.

###



CONTACT:

Cmed Group
Christopher Leary
+1 908-795-2006
[email protected]
or
Ally Baker
+44 (0)1403 756471
[email protected]

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Technology  Data Management  Software  Health  Clinical Trials  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.